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Pulmonary arterial hypertension (PAH) is a progressive disease
haracterized by vascular remodeling of small- to medium-sized
ulmonary arteries, resulting in elevated pulmonary arterial pres-
ure (PAP) and ultimately in right heart failure and death. Advanced
AH is characterized by arteriopathy, which includes musculariza-
ion of distal pulmonary arterioles, concentric intimal thickening,
nd obstruction of the vascular lumen by proliferating endothelial
ells, resulting in plexiform lesions [1]. Pulmonary vasoconstriction
nd vascular remodeling are associated with substantial number
f molecules and cellular substrates, a concept referred to as the
multiple-hit-theory” [2] (Fig. 1).
Prostacyclin (PGI2) is one of the most potent intrinsic vasodila-
ors with anti-proliferative effects and is produced by endothelial
ells. A classically known signaling pathway of PGI2 is activated
y the rhodopsin type G protein-coupled cell surface receptor
ermed IP. Its effectiveness in the treatment of PAH, a condition in
hich patients have reduced IP receptor expression in the remod-
led pulmonary arterial smooth muscle cells (PASMCs), has been
rmly established in various clinical conditions [3]. IP receptor deﬁ-
ient mice exhibit more severe vascular remodeling in response to
ypoxia, and are more susceptible to thrombosis, suggesting that
he beneﬁcial effects of PGI2 in the treatment of PAH might be
xerted via activation of the IP receptor signaling pathway. Trans-
enic mice with selective pulmonary overexpression of the PGI2
ynthase gene were protected against the development of hypoxia-
nduced pulmonary hypertension. Moreover, PGI2 and its analogs
ad also been reported to prevent pressure overload-induced car-
iac hypertrophy [4], and to reduce cardiac ischemia/reperfusion
njury via the membrane receptor IP [5].
Previously, a novel signaling pathway of PGI2 and its analogs
hrough peroxisome proliferator-activated receptor (PPAR) had
een demonstrated in adipocytes, lung ﬁbroblasts, and uterine cells
t the site of implantation. We  demonstrated for the ﬁrst time that
PGI2, a PGI2 analog, induces expression of an enzyme involved in
itochondrial fatty acid -oxidation in cardiomyocytes via PPAR
6].
Intravenous PGI2 is the ﬁrst drug to provide appreciable beneﬁts
n patients with idiopathic PAH (IPAH). The treatment algorithm
ttp://dx.doi.org/10.1016/j.jccase.2014.02.004
878-5409 © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. Open accesFig. 1. Multiple-hits-theory and vascular remodeling.
of PAH was  updated at the 5th World Symposium on Pulmonary
Hypertension held in Nice, France, in February/March 2013, and
the conclusion of each task force was published in the Journal of
the American College of Cardiology in December 2013. Intravenous
epoprostenol (EPO) is recommended as Class I and Level A in World
Health Organization functional class III and IV PAH patients in the
most current treatment algorithm [7]. In addition, EPO and maci-
tentan were highlighted because morbidity and mortality were
applied as primary end-point in randomized controlled studies of
these drugs [7].
In  2010, there was  an interesting report that IPAH patients
receiving high-dose PGI2 showed marked hemodynamic improve-
ment [8]. They were treated with 107 ± 40 ng/kg/min EPO for
1355 ± 627 days, and subsequently mean PAP decreased from
66 ± 16 to 47 ± 12 mmHg, and more importantly all the patients
survived for a period of 3.7 years. The appropriate dose range of EPO
is thought to be 25–40 ng/kg/min based on the previous studies [9],
and until recently the efﬁcacy of treatment of IPAH patients with
EPO >40 ng/kg/min had not been determined. They concluded that
for better survival, a treatment with EPO >40 ng/kg/min is required
to achieve a marked hemodynamic improvement.
s under CC BY-NC-ND license.
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Hemodynamic parameters are considered to be the gold stan-
ard indices of outcome in PAH patients. The National Institutes of
ealth registry demonstrated that increased mean PAP, increased
ean right atrial pressure (RAP), and decreased cardiac index
CI) were associated with an increased mortality. Since then,
emodynamics, speciﬁcally, RAP, CI and mixed-venous oxygen
aturation (SvO2) have been conﬁrmed in numerous studies as
obust independent prognostic factors [10]. There are still several
aveats and limitations in using hemodynamic parameters to
ssess prognosis. Mean PAP has not been included as a variable
o determine response to therapy and prognosis in PAH patients
t follow-up period. In addition, even for the CI, there is no strong
vidence for the current recommendation of CI >2.5 L/min/m2
s a hemodynamic goal, as it was derived mainly from studies
valuating patients with left heart failure [11].
PAH is a vascular proliferative disease characterized by
bnormal proliferation and impaired apoptosis of PASMCs. The
evelopment of medical agents with anti-proliferative and pro-
poptotic effects in PASMCs would provide a novel therapeutic
odality for PAH. Evidence from animal models and human dis-
ase suggest that platelet-derived growth factor (PDGF) and c-KIT
ignaling are important in vascular smooth muscle cell (VSMC) pro-
iferation and hyperplasia. Imatinib is an anti-proliferative agent
eveloped to target Bcr-Abl tyrosine kinase in patients with chronic
yeloid leukemia. The inhibitory effect of imaninib on PDGF recep-
ors and c-KIT suggests that it may  be efﬁcacious in PAH. Imatinib
nd sorafenib, a multi-kinase inhibitor, are reported to present
nti-proliferative effects and induce apoptosis in PDGF stimulated
AH-PASMCs [12] and reverse PAH in an animal model of pul-
onary hypertension [13]. However, induction of apoptosis by
matinb is controversial. Furthermore, two randomized controlled
rials in PAH patients treated with imatinib have shown positive
esults on exercise capacity and hemodynamics, in association with
ncreased incidence of subdural hematoma in the patients treated
ith both imatinib and oral anticoagulants [14].
Recently, Akagi et al. reported [15] that in an in vitro study, PGI2
nduced apoptosis in PASMCs from IPAH patients. They showed
hat terminal deoxynucleotidyl transferase dUTP nick end labeling-
ositive, caspase-3 active cells were detected in PASMCs obtained
rom eight IPAH patients after treatment with high-dose PGI2 but
ot with low-dose PGI2. An IP receptor antagonist inhibited the
nduction of apoptosis, elevation of cyclic AMP, and upregulation
f Fas ligand induced by high-dose PGI2, and induction of apopto-
is was not observed in PASMCs obtained from non-PAH patients.
urthermore, serum Fas ligand level showed a signiﬁcant positive
orrelation with PGI2 dose in PGI2-treated PAH patients.
In  this issue of the Journal of Cardiology Cases, Akagi et al. further
emonstrated reverse vascular remodeling and apoptotic cells in
ulmonary vasculature in lung tissue from an IPAH patient treated
ith high-dose PGI2 [16]. This report is a continuation of their pre-
ious study, and although a single case, they proposed that reverse
emodeling of the pulmonary arteries would be a direct effect of
igh-dose PGI2. However, the mean PAP was markedly improved in
his patient, whereas it was unchanged in the patient who was  not
reated with PGI2. For reverse vascular remodeling in IPAH patients,
he signiﬁcance of lowering PAP is an issue to be considered. In
ddition, the underlying mechanisms of why only high-dose but
ot low-dose PGI2 transduces apoptotic signal in PASMCs have not
een clariﬁed to date.
Many  medications other than EPO are now available or will be
vailable in the near future, including as a novel endothelin recep-
or antagonist, soluble guanylate cyclase stimulator, Rho-kinase
nhibitor, several growth factors inhibitors, etc. Although the new
ra is welcomed, we do not yet have a thorough understanding of
he usage of new drugs and interactions contributing to improved Cases 9 (2014) 177–178
quality  of life and better survival. The evidence of apoptotic cells
in pulmonary vasculature in IPAH patients treated with high-dose
PGI2 will strongly encourage future exploration of effective treat-
ment options for managing patients with severe PAH.
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